Research ExplorerPublicationsOnce daily dolutegravir (S/GSK1349572) in combination therap...

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

Standard

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. / van Lunzen, Jan; Maggiolo, Franco; Arribas, José R; Rakhmanova, Aza; Yeni, Patrick; Young, Benjamin; Rockstroh, Jürgen K; Almond, Steve; Song, Ivy; Brothers, Cindy; Min, Sherene.

In: LANCET INFECT DIS, Vol. 12, No. 2, 2, 2012, p. 111-118.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

van Lunzen, J, Maggiolo, F, Arribas, JR, Rakhmanova, A, Yeni, P, Young, B, Rockstroh, JK, Almond, S, Song, I, Brothers, C & Min, S 2012, 'Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.', LANCET INFECT DIS, vol. 12, no. 2, 2, pp. 111-118. <http://www.ncbi.nlm.nih.gov/pubmed/22018760?dopt=Citation>

APA

van Lunzen, J., Maggiolo, F., Arribas, J. R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J. K., Almond, S., Song, I., Brothers, C., & Min, S. (2012). Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. LANCET INFECT DIS, 12(2), 111-118. [2]. http://www.ncbi.nlm.nih.gov/pubmed/22018760?dopt=Citation

Vancouver

van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. LANCET INFECT DIS. 2012;12(2):111-118. 2.

Bibtex

@article{a7501c3c64c940a2a8d8b1874e36e4f4,
title = "Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.",
abstract = "Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral activity with once daily, unboosted dosing. SPRING-1 is an ongoing study designed to select a dose for phase 3 assessment. We present data from preplanned primary and interim analyses.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Young Adult, Viral Load, Dose-Response Relationship, Drug, RNA, Viral/blood, Virus Replication/drug effects, Benzoxazines/administration & dosage, HIV Infections/*drug therapy/metabolism/virology, HIV Integrase Inhibitors/*administration & dosage, HIV-1/*physiology, Heterocyclic Compounds, 3-Ring/*administration & dosage, Reverse Transcriptase Inhibitors/administration & dosage, Adult, Humans, Male, Aged, Female, Middle Aged, Young Adult, Viral Load, Dose-Response Relationship, Drug, RNA, Viral/blood, Virus Replication/drug effects, Benzoxazines/administration & dosage, HIV Infections/*drug therapy/metabolism/virology, HIV Integrase Inhibitors/*administration & dosage, HIV-1/*physiology, Heterocyclic Compounds, 3-Ring/*administration & dosage, Reverse Transcriptase Inhibitors/administration & dosage",
author = "{van Lunzen}, Jan and Franco Maggiolo and Arribas, {Jos{\'e} R} and Aza Rakhmanova and Patrick Yeni and Benjamin Young and Rockstroh, {J{\"u}rgen K} and Steve Almond and Ivy Song and Cindy Brothers and Sherene Min",
year = "2012",
language = "English",
volume = "12",
pages = "111--118",
journal = "LANCET INFECT DIS",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "2",

}

RIS

TY - JOUR

T1 - Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

AU - van Lunzen, Jan

AU - Maggiolo, Franco

AU - Arribas, José R

AU - Rakhmanova, Aza

AU - Yeni, Patrick

AU - Young, Benjamin

AU - Rockstroh, Jürgen K

AU - Almond, Steve

AU - Song, Ivy

AU - Brothers, Cindy

AU - Min, Sherene

PY - 2012

Y1 - 2012

N2 - Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral activity with once daily, unboosted dosing. SPRING-1 is an ongoing study designed to select a dose for phase 3 assessment. We present data from preplanned primary and interim analyses.

AB - Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral activity with once daily, unboosted dosing. SPRING-1 is an ongoing study designed to select a dose for phase 3 assessment. We present data from preplanned primary and interim analyses.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Viral Load

KW - Dose-Response Relationship, Drug

KW - RNA, Viral/blood

KW - Virus Replication/drug effects

KW - Benzoxazines/administration & dosage

KW - HIV Infections/drug therapy/metabolism/virology

KW - HIV Integrase Inhibitors/administration & dosage

KW - HIV-1/physiology

KW - Heterocyclic Compounds, 3-Ring/administration & dosage

KW - Reverse Transcriptase Inhibitors/administration & dosage

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Viral Load

KW - Dose-Response Relationship, Drug

KW - RNA, Viral/blood

KW - Virus Replication/drug effects

KW - Benzoxazines/administration & dosage

KW - HIV Infections/drug therapy/metabolism/virology

KW - HIV Integrase Inhibitors/administration & dosage

KW - HIV-1/physiology

KW - Heterocyclic Compounds, 3-Ring/administration & dosage

KW - Reverse Transcriptase Inhibitors/administration & dosage

M3 - SCORING: Journal article

VL - 12

SP - 111

EP - 118

JO - LANCET INFECT DIS

JF - LANCET INFECT DIS

SN - 1473-3099

IS - 2

M1 - 2

ER -